|
Dr. Reddy’s eyes $50-60 mn US market for anti-narcotic addiction generic drug cleared by US Appeals court
|
|
A Raju, Hyderabad
November 30 , 2018
|
|
|
With a recent US Court of Appeals delivering a favourable decision to allow Suboxone an anti-narcotic addiction generic medicine manufactured by Hyderabad-based Dr. Reddy’s Laboratories into US markets, the company authorities are hoping to capture a market of US$ 50-60 million for their generic medicine during the current financial year.
According to sources from Dr. Reddy’s Laboratories, the generic medicine Suboxone, manufactured by the company had to face temporary legal hurdles in the US. However, with the appeals court recently delivering a favourable decision, the company authorities are now taking all necessary steps and preparing for a smooth launch of the medicine in the US markets. “Getting a favourable decision from the appeals court is a big breakthrough for Dr. Reddy’s Laboratories. We are taking all necessary steps to launch the product at the earliest to take advantage of the highly potential US market,” said the source.
In fact, earlier in June the US Food and Drug Administration (US FDA) approved Dr. Reddy’s buprenorphine and naloxone (Suboxone) sublingual film for sale in the US market and the company had also launched the product immediately after approval.
However, with litigations filed in the District court relating to infringement of US patent, it temporarily halted the sales and commercialisation activities due to the District Court’s injunction order restraining Dr. Reddy’s generic product into US market.
Now with the Appeals court vacating the preliminary injunction to restrict Dr. Reddy’s Suboxone generic product into US markets, the company authorities are jubilant and taking all necessary measures to launch its products into the US markets and expecting a considerable market share in the current financial year.
The new generic drug Suboxone is quite effective in treating patients who are addicted to narcotic drugs like morphine, oxycodine, fentanyl and buprenorphine. As the demand for anti-narcotic addiction drug is very high in USA, Dr. Reddy’s laboratories, is eyeing higher returns from the US markets for the current financial year.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|